The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.
 
Chris Burns
Employment - Amplia Therapeutics
Leadership - Amplia Therapeutics
Stock and Other Ownership Interests - Amplia Therapeutics
Patents, Royalties, Other Intellectual Property - Amplia Therapeutics
 
Terrie-Anne Cock
Employment - Amplia Therapeutics
Leadership - Amplia Therapeutics
Stock and Other Ownership Interests - Amplia Therapeutics
Research Funding - Amplia Therapeutics
 
Anthony Bishop
Employment - Amplia Therapeutics
Leadership - Amplia Therapeutics
Stock and Other Ownership Interests - Amplia Tt
Research Funding - Amplia Therapeutics
 
Nicole Kruger
Employment - Amplia Therapeutics
Leadership - Amplia Therapeutics
Stock and Other Ownership Interests - Amplia Therapeutics
Research Funding - Amplia Therapeutics
 
Sarah McCormack
Employment - Amplia Therapeutics
Stock and Other Ownership Interests - Amplia Therapeutics
Research Funding - Amplia Therapeutics
 
Sumitra Ananda
No Relationships to Disclose
 
Marion Harris
No Relationships to Disclose
 
Warren Lance Joubert
No Relationships to Disclose
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
 
Choong-kun Lee
Honoraria - Boryung; Dong-A ST; Novartis; SERVIER
Consulting or Advisory Role - AstraZeneca
 
Woo Jin Lee
No Relationships to Disclose
 
Larissa Rachel Lipton
No Relationships to Disclose
 
Adnan Nagrial
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology
Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Joon Oh Park
Consulting or Advisory Role - ABL Bio; Adicet Bio; Arcus Biosciences; AstraZeneca; Celgene; ImmuneOncia; Intocell; MediRama; Merck Serono; SERVIER
Research Funding - ABL Bio; Celgene; Eutilex; medpacto; SERVIER
Travel, Accommodations, Expenses - Minneamrita Therapeutics
 
Nick Pavlakis
Honoraria - Bayer; BeiGene; BeiGene; Pierre Fabre; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Merck KGaA; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - Bayer (Inst); Pfizer (Inst); Roche (Inst)
 
Jason Lickliter
Consulting or Advisory Role - Amplia Therapeutics